| Literature DB >> 33923916 |
Lam Van Nguyen1, Thao N P Nguyen2, Anh N Thach3, Anh N Lam4, Duc Q Lam2, Chu X Duong2, Suol T Pham2, Thao H Nguyen5, Dyah A Perwitasari6, Katja Taxis7, Phuong M Nguyen8, Thang Nguyen2.
Abstract
This study aimed to assess the knowledge of antiretroviral (ARV) treatment and the associated factors in HIV-infected patients in Vietnam. We conducted a cross-sectional descriptive study of 350 human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) patients being treated with ARV at outpatient clinics at Soc Trang, Vietnam, from June 2019 to December 2019. Using an interview questionnaire, patients who answered at least eight out of nine questions correctly, including some required questions, were considered to have a general knowledge of ARV treatment. Using multivariate logistic regression to identify factors associated with knowledge of ARV treatment, we found that 62% of HIV-infected patients had a general knowledge of ARV treatment, with a mean score of 8.2 (SD 1.4) out of 9 correct. A higher education level (p < 0.001); working away from home (p = 0.013); getting HIV transmitted by injecting drugs or from mother-to-child contact (p = 0.023); the presence of tension, anxiety, or stress (p = 0.005); self-reminding to take medication (p = 0.024); and a high self-evaluated adherence (p < 0.001) were found to be significantly associated with an adequate knowledge of ARV treatment. In conclusion, education programs for patients, as well as the quality of medical services and support, should be strengthened.Entities:
Keywords: ARV; HIV/AIDS; Vietnam; knowledge
Year: 2021 PMID: 33923916 PMCID: PMC8073643 DOI: 10.3390/healthcare9040483
Source DB: PubMed Journal: Healthcare (Basel) ISSN: 2227-9032
Figure 1Enrollment of participants.
Study population characteristics: demography, antiretroviral (ARV) treatment, and medical services and support.
| Characteristics | General Knowledge of ARV Treatment | Unadjusted | |||
|---|---|---|---|---|---|
| Yes | No | OR | |||
|
| |||||
| <35 years | 162 (46.3) | 106 (65.4) | 56 (34.6) | 1.31 | 0.219 |
| ≥35 years | 188 (53.7) | 111 (59.0) | 77 (41.0) | (0.85–2.03) | |
|
| |||||
| Male | 220 (62.9) | 139 (63.2) | 81 (36.8) | 1.14 | 0.553 |
| Female | 130 (37.1) | 78 (60.0) | 52 (40.0) | (0.73–1.79) | |
|
| |||||
| <20 km | 108 (30.9) | 70 (64.8) | 38 (35.2) | 1.19 | 0.469 |
| ≥20 km | 242 (69.1) | 147 (60.7) | 95 (39.3) | (0.74–1.91) | |
|
| |||||
| Secondary school or more | 206 (58.9) | 151 (73.3) | 55 (26.7) | 3.25 | <0.001 |
| Less than secondary school | 144 (41.1) | 66 (45.8) | 78 (54.2) | (2.07–5.09) | |
|
| |||||
| Currently employed | 285 (81.4) | 183 (64.2) | 102 (35.8) | 1.64 | 0.074 |
| Unemployed | 65 (18.6) | 34 (52.3) | 31 (47.7) | (0.95–2.82) | |
|
| |||||
| Yes | 135 (38.6) | 96 (71.1) | 39 (28.9) | 1.91 | 0.005 |
| No | 215 (61.4) | 121 (56.3) | 94 (43.7) | (1.21–3.03) | |
|
| |||||
| Injecting drugs or mother-to-child contact | 17 (4.9) | 15 (88.2) | 2 (11.8) | 4.86 | 0.022 |
| Sexual intercourse | 333 (95.1) | 202 (60.7) | 131 (39.3) | (1.09–21.62) | |
|
| |||||
| No | 340 (97.1) | 212 (62.4) | 128 (37.6) | 1.66 | 0.514 * |
| Yes | 10 (2.9) | 5 (50.0) | 5 (50.0) | (0.47–5.83) | |
|
| |||||
| No | 106 (30.3) | 71 (67.0) | 35 (33.0) | 1.36 | 0.206 |
| Yes | 244 (69.7) | 146 (59.8) | 98 (40.2) | (0.84–2.20) | |
|
| |||||
| Yes | 160 (45.7) | 115 (71.9) | 45 (28.1) | 2.21 | <0.001 |
| No | 190 (54.3) | 102 (53.7) | 88 (46.3) | (1.41–3.45) | |
|
| |||||
| Better | 239 (68.3) | 164 (68.6) | 75 (31.4) | 2.39 | <0.001 |
| Normal | 111 (31.7) | 53 (47.7) | 58 (52.3) | (1.51–3.80) | |
|
| |||||
| No | 294 (84) | 193 (65.6) | 101 (34.4) | 2.55 | 0.001 |
| Yes | 56 (16) | 24 (42.9) | 32 (57.1) | (1.43–4.56) | |
|
| |||||
| Self-remind | 293 (83.7) | 193 (65.9) | 100 (34.1) | 2.65 | 0.001 |
| Spouses, parents, siblings | 57 (16.3) | 24 (42.1) | 33 (57.9) | (1.49–4.73) | |
|
| |||||
| High adherence | 282 (80.6) | 194 (68.8) | 88 (31.2) | 4.31 | <0.001 |
| Medium and low adherence | 68 (19.4) | 23 (33.8) | 45 (66.2) | (2.46–7.57) | |
* Fisher’s Exact Test.
Knowledge of ARV treatment.
| Question | Frequency | Percentage (%) |
|---|---|---|
|
| ||
| Antivirals (correct) | 320 | 91.4 |
| Antibiotics/do not know | 30 | 8.6 |
|
| ||
| Triple ARVs or more (correct) | 251 | 71.7 |
| Do not know | 99 | 28.3 |
|
| ||
| Lifelong (correct) | 341 | 97.4 |
| Other duration/do not know | 9 | 2.6 |
|
| ||
| Once daily (q.24.h) or twice daily (q.12.h) (correct) | 343 | 98.0 |
| Do not know | 7 | 2.0 |
|
| ||
| Rash, headache/dizziness, nausea/vomiting, diarrhea, stomachache, anemia, hepato-renal toxicity, etc. (correct) | 334 | 95.4 |
| Do not know | 16 | 4.6 |
|
| ||
| Consult with physicians (correct) | 320 | 91.4 |
| Self-manage/do not know | 30 | 8.6 |
|
| ||
| Take it as soon as you remember (correct) | 311 | 88.9 |
| Skip the missed dose/do not know | 39 | 11.1 |
|
| ||
| Take the next dose 4 h after taking the missed dose (for the twice-daily regimen) or 12 h (for the once-daily regimen) (correct) | 328 | 93.7 |
| Do not know | 22 | 6.3 |
|
| ||
| Take the right medicine, right dose, at the right time, in the right way, and re-examine on time (correct) | 338 | 96.6 |
| Do not know | 12 | 3.4 |
|
| 217 | 62.0 |
|
| ||
Factors associated with knowledge regarding ARV treatment.
| Covariate | Adjusted | |
|---|---|---|
| OR | ||
|
| ||
| Secondary school or more | 2.54 (1.56–4.13) | <0.001 |
| Less than secondary school | ||
|
| ||
| Yes | 1.91 (1.14–3.18) | 0.013 |
| No | ||
|
| ||
| Injecting drugs or mother-to-child contact | 6.65 (1.29–34.07) | 0.023 |
| Sexual intercourse | ||
|
| ||
| Yes | 2.04 (1.24–3.34) | 0.005 |
| No | ||
|
| ||
| Self-remind | 2.12 (1.1–4.06) | 0.024 |
| Spouses, parents, siblings | ||
|
| ||
| High adherence | 4.06 (2.17–7.57) | <0.001 |
| Medium and low adherence | ||